ImmunoPrecise Antibodies (IPA)
(Real Time Quote from BATS)
$1.03 USD
-0.06 (-5.51%)
Updated Jun 4, 2024 03:36 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
IPA 1.03 -0.06(-5.51%)
Will IPA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IPA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IPA
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
New Strong Buy Stocks for February 7th
IPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for February 5th
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
New Strong Buy Stocks for October 23rd
Other News for IPA
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
BioStrand Leads Innovation in Precision Medicine
ImmunoPrecise Antibodies announces expansion of LENS platform
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
ImmunoPrecise Antibodies, InterSystems partner to leverage AI in life sciences